Related Experiment Video

Updated: Jun 4, 2025

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:25

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

175

Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports

Maryann R Chapin1, Sandra L Kane-Gill1,2, Xiaotong Li1

  • 1School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Pharmacology Research & Perspectives
|December 25, 2024
PubMed

Insights

Pediatric use of cannabis with certain medications may increase adverse drug reactions. Caution is advised due to potential drug interactions between cannabinoids and pharmaceuticals in children.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Safety

Background:

  • Limited data exists on drug interactions between cannabis products and pharmaceuticals in pediatric patients.
  • Cannabis and cannabinoid-derived products are increasingly used, necessitating safety evaluations.

Purpose of the Study:

  • To identify potential drug interactions between cannabis/cannabinoids and pharmaceutical medications in individuals under 18 years old.
  • To evaluate the safety of co-administering cannabis with prescribed drugs in pediatric populations.

Main Methods:

  • Literature search of PubMed for case reports and analysis of Food and Drug Administration's Adverse Event Reporting System (FAERS) data.
  • Utilized the Drug Interaction Probability Scale (DIPS) to assess causality in published case reports.
  • Analyzed 9142 FAERS reports for patient demographics, associated drugs, adverse drug reactions (ADRs), and outcomes.

Main Results:

  • Seven published case reports and 9142 FAERS reports were analyzed.
  • Identified potential interactions between cannabis/cannabinoids and medications such as methadone, everolimus, fluoxetine, and paroxetine.
  • Cannabinoids may inhibit cytochrome P450 enzymes, increasing drug exposure and risk of ADRs.

Conclusions:

  • Caution is warranted when combining cannabis or cannabinoids with prescribed medications in pediatric patients.
  • Potential inhibition of drug-metabolizing enzymes by cannabinoids can lead to increased drug exposure and adverse events.
  • Further research is needed to fully understand and manage these drug interactions in children.

Keywords:
adolescentscannabidiolcannabisdrug interactionsmedication safetynatural productspediatrics

More Related Videos

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.5K
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

19

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
201
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.3K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
80